Amber Barkley is a writer and editor with over 10 years of experience in topics ranging from personal finance to marketing analytics to fiction. She found her niche in personal finance in 2022, when ...

Ben O'Mahony discusses building custom AI-powered Language Server Protocols (LSPs) that go beyond standard rule-based ...

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a more restrictive label than ...